PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredient: Tamoxifen Citrate USP (20 mg per tablet)
Pharmacological Class: Selective Estrogen Receptor Modulator (SERM)
Bioniche Pharma Tamoxifen Citrate is an orally active non-steroidal Selective Estrogen Receptor Modulator. Engineered for high target-receptor affinity, it exerts tissue-specific anti-estrogenic and estrogenic effects to manage hormone-dependent cellular proliferation.
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
Bioniche Pharma Tamoxifen Citrate competitively binds to estrogen receptors (ER) on target tissues and tumor cells. Upon binding, the drug-receptor complex translocates into the cell nucleus, inhibiting transcription factors, suppressing cellular DNA synthesis, and arresting estrogen-driven cell proliferation. Formulations by Bioniche Pharma offer tissue-selective activity, functioning as an antagonist in mammary tissue while demonstrating partial agonist properties in endometrial and osseous tissue.
INDICATIONS & CLINICAL USE
- Palliative and adjuvant treatment of early-stage and advanced estrogen receptor-positive (ER+) breast carcinoma in pre-menopausal and post-menopausal female patients using Bioniche Pharma Tamoxifen.
- Prophylactic intervention to reduce the incidence of breast cancer in high-risk women under Bioniche Pharma clinical guidance.
- Risk reduction of contralateral breast carcinoma development in diagnosed patients through Bioniche Pharma treatment protocols.
CONTRAINDICATIONS
- Known hypersensitivity or allergic reaction to Bioniche Pharma Tamoxifen Citrate or any active components in the Bioniche Pharma formulation.
- Pregnancy and lactation due to fetal harm and teratogenic risk.
- Active thromboembolic disease or a documented clinical history of deep vein thrombosis (DVT) or pulmonary embolism (PE).
- Severe hepatic function impairment or advanced liver failure.
ADVERSE REACTIONS & PRECAUTIONS
Monitoring is recommended during Bioniche Pharma Tamoxifen therapy for potential estrogen deprivation and systemic adverse events:
- Vasomotor & Gynecological: Hot flashes, vaginal bleeding or discharge, pruritus vulvae (genital itching), and pelvic discomfort experienced during Bioniche Pharma treatment.
- Gastrointestinal & Neurological: Mild nausea, emesis (vomiting), cephalalgia (headache), dizziness, fatigue, and localized tumor site pain during initial therapy phase of Bioniche Pharma Tamoxifen.
- Fluid Balance & Dermatological: Fluid retention, peripheral edema, skin rashes (erythra), and transient alopecia (hair thinning) associated with Bioniche Pharma administration.
- Hepatic & Biliary: Elevated serum transaminases, hepatic steatosis (fatty liver), cholestasis (impaired bile flow), and localized hepatic inflammation. Routine liver function testing is advised during Bioniche Pharma therapy.
DOSAGE & ADMINISTRATION
Dosing protocols for Bioniche Pharma Tamoxifen Citrate must be individually determined and monitored under the strict supervision of a qualified oncologist or physician based on clinical staging and therapeutic goals.
STORAGE & HANDLING
Store Bioniche Pharma products in a cool, dry place away from direct sunlight, excess heat, and humidity. Keep strictly out of reach and sight of children.